BOSTON, Aug. 2, 2012 /PRNewswire/ -- PAREXEL Consulting, a business unit of PAREXEL International (NASDAQ: PRXL) and a leading global consultancy serving the biopharmaceutical and medical device ...

In a recent press release from Microsoft Corp. and PAREXEL International Corp., a leading global biopharmaceutical services organization, on Tuesday announced a technology development alliance aimed ...

First-quarter results reflect tough competition in this company's industry. PAREXEL International (NASDAQ:PRXL) is having no trouble winning contracts. But the contract research organization's ...

The collaboration between Parexel and Partex is designed to leverage artificial intelligence-powered solutions to accelerate drug discovery and development. Parexel, a clinical research organization ...

Goldman Sachs’ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member Jo Natauri who is retiring from the firm at the end of the ...

BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced its enhanced Global Data Operations (GDO) solution, with augmented ...

EQT Private Equity and the private equity business of Goldman Sachs Asset Management announced the acquisition agreement Friday. The deal comes four years after Parexel was purchased by Pamplona ...

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and ...

Like most industries, the biopharmaceutical space is undergoing a radical evolution. The sector, for quite some time now, has been embracing – and necessitating – the use of big data and sophisticated ...

Parexel is being acquired by Pamplona Capital Management in a $5 billion deal that will make the pharmaceutical contract researcher a private company. The private equity fund manager said Tuesday that ...

The price tag for HERON is $24 million, plus a potential extra $14.2 million. The immediate cost of the acquisition was $24 million, which was funded through PAREXEL's existing cash resources. The ...